Granegis (Granisetron)

Granegis is indicated for the prevention and treatment of nausea and vomiting related to specific medical procedures.

• Chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Post‑operative nausea and vomiting (PONV) following surgical procedures.
• Nausea associated with radiation therapy.
• Nausea caused by diagnostic procedures that use emetogenic agents.

The safety profile of granisetron includes both common and less frequent adverse events, most of which are mild and transient.

Common

• Headache.
• Constipation.
• Dizziness.
• Fatigue.

Serious

• QT interval prolongation.
• Severe allergic reaction (anaphylaxis).
• Serotonin syndrome (rare).

Before initiating therapy with Granegis, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess cardiac history, especially for patients with known QT prolongation.
• Use cautiously in patients with electrolyte disturbances (e.g., low potassium or magnesium).
• Evaluate renal and hepatic function; dose adjustment may be required in severe impairment.
• Consider alternative antiemetics in patients with known hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Discuss potential risks with pregnant or breastfeeding women, as safety data are limited.
• Monitor for signs of severe constipation or bowel obstruction during treatment.

Granisetron may interact with other medications, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics).
• Combination with other 5‑HT3 antagonists, as this provides no added benefit and may increase toxicity.

Use with caution

• Co‑administration with drugs that affect electrolyte balance (e.g., diuretics).
• Use with CYP3A4 inhibitors or inducers, which could alter granisetron plasma levels.
• Concomitant use with serotonergic agents (e.g., SSRIs) requires monitoring for serotonin syndrome.